Menarini signs pan-Asian distribution deal for inhaler product

4 July 2018

The Singaporean business of Italy’s Menarini has agreed a multi-year deal with Orion Corporation to distribute and commercialize several of Orion’s Easyhaler products.

The deal relates to 10 countries in the region, including China, Hong Kong and South Korea. Orion’s proprietary dry-powder inhaler product is used for administering medication for the treatment of asthma and COPD.

Menarini Asia-Pacific chief executive Albert Lim said: “Menarini has engaged in respiratory therapeutic area for many years, particularly asthma and COPD. It is one of the key areas of development for Menarini. Orion’s products will contribute strongly to the expansion of our respiratory portfolio.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK